Huma

Huma is a UK-based clinical trial tech startup that provides a digital platform to manage clinical trials, including decentralized clinical trials. The platform can be used throughout the clinical trial process, including patient recruitment, screening, electronic consent, clinical outcome assessments, patient-reported outcomes, and telemedicine. The platform is built up to industry standards in data privacy and security, including ISO 27001, 21 C.F.R. Part 11, and TxP.

In June 2023, the company received FDA 510(k) Class II FDA clearance for its configurable disease-agnostic platform, including its cardiovascular risk score algorithm. The company received this FDA clearance in partnership with Health Canada and it allows Huma's platform to be used to monitor patients of all ages with any condition, including pediatrics and pregnancy. The Class II clearance also enables the platform to host algorithms that provide automated AI-driven data analytics for diagnosis, screening, clinical decision-making, predictions on health outcomes, and recommendations on dosage.

Key customers and partnerships

Some of the key partners working with Huma include AstraZeneca, Johnson & Johnson, Bayer, Stanford University, and the University of Cambridge. As of May 2022, the platform supported more than 3,000 hospitals and clinics with more than 1.8 million active users on the platform. Huma was awarded the 2022 Prix Galien Award, which is widely considered the “Nobel Prize” for pharmaceuticals and life sciences.

The company announced a partnership with Xyla Elective Care in June 2022, to provide support to the UK’s National Health Service in delivering and managing virtual wards.

Funding and financials

Huma raised USD 33 million from AstraZeneca in March 2022 as a strategic investment. Additionally, as part of the agreement, the companies are to launch new products for software-as-a-medical-device (SaMD), including customized software development of SaMD companion apps for customers.